Fundraising Fox
Imbria
Founded 2018 · 16 employees on LinkedIn · 6 known investors
Find your way into Imbria
1,402 people in our graph can introduce you to the Imbria team.
Sign up to see every warm intro you have to Imbria
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Imbria team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy. It focuses on therapies for patients with limited treatment options in cardiometabolic and cardiovascular conditions.
Founders & leadership
Investors · 6
How we know: AN Venture Partners's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · press coverage · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: SV Health Investors's portfolio page · press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
Founder mafia
3 people who came through Imbria went on to found or lead other companies.
In the news
Frequently asked questions
- What does Imbria do?
- Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy. It focuses on therapies for patients with limited treatment options in cardiometabolic and cardiovascular conditions.
- Who are Imbria's investors?
- Imbria's investors include AN Venture Partners, Catalio Capital Management, LP, RA Capital, Sanofi Ventures, SV Health Investors, Catalio Capital Management.